0 results for 'undefined'
Bradley Arant Sees Revenues Rise and PEP Fall Amid 12% Equity Partner Expansion
The firm's PEP dropped by 5% to $820,000, as its equity tier expanded and its nonequity tier shrunk by 9%, bucking a trend in the industry of growing the nonequity ranks.About the Awards: Southeastern Legal Awards Q&A With Regional Managing Editor Michael Marciano
Deadline is looming for nominations in the 2024 Southeastern Legal Awards.Slower Collections Test Boundaries of Attorney-Client Relationships
Prominent law firms are finding themselves adverse to former clients in unpaid fee litigation as collection cycles lengthen, but not every dispute is worth litigating.Sullivan & Cromwell's 'Man on the Inside': Lawsuit Throws Spotlight on Former FTX GC
Ryne Miller is not a defendant in the shareholder lawsuit, but it asserts he helped funnel millions of dollars in work to Sullivan & Cromwell after he left the firm to join FTX in 2021.Lawsuit Throws Spotlight on Former FTX GC, Calls Him Sullivan & Cromwell's 'Man on the Inside'
Ryne Miller is not a defendant in the shareholder lawsuit, but it asserts he helped funnel millions of dollars in work to Sullivan & Cromwell after he left the firm to join FTX in 2021.View more book results for the query "*"
What the Fifth Circuit's Ruling on Avoidance Actions Means for Debtors
"While the Fifth Circuit's decision put to bed a longstanding question of law, it also gives rise to many others," writes John Kane of Kane Russell Coleman Logan.Georgia Churches, Nonprofits Ensnared in Push to Restrict Bail Funds
Wide-scale initiatives that pay for for her pretrial release could be significantly restricted, if not criminalized, under a Georgia bill awaiting Gov. Brian Kemp's signature.Treatment of Antibody Claims In the U.S. After 'Amgen v. Sanofi'
The future of antibody claiming in the United States is uncertain following the U.S. Supreme Court's ruling in 'Amgen Inc. v. Sanofi,' a highly anticipated decision concerning enablement and whether the traditional way to claim antibodies — claiming antibodies by their function — will survive as a valid claiming strategy.Faegre Drinker Rebounds From 2022 With Double-Digit PEP Growth
"We saw these huge gains in litigation, including product liability, intellectual property, class actions, appellate work," said Chair Gina Kastel, who is close to completing her first year in the role.Biden Nominates Judges for 7th Circuit, DC, Illinois, Arizona District Courts
Nancy Maldonado would be the first Hispanic judge on the Chicago-based federal appeals court.Trending Stories
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250
2024 Report: State of AI in Legal
Brought to you by Ironclad
Download Now
Blueprint for Successful Second Request Document Review
Brought to you by Integreon
Download Now
Employee Happiness Playbook: The 3 R's for Business Success in 2024
Brought to you by Amazing Workplace, Inc.
Download Now
The Positive Impact of AI at Small Law Firms: 4 Key Insights
Brought to you by LexisNexis®
Download Now